All In Biotech

Drug Trial Radar · NCT07678593

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

222

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Nov 2027

Study completion Sep 2028

Sponsor

Sponsor type
Industry
First posted
Jul 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Conditions

  • Advanced Solid Tumors Cancer
  • Pancreatic Ductal Adenocarcinoma
  • RAS Mutation

Interventions

  • GFH276Drug

    Oral GFH276 administered once daily in combination with other study drugs.

  • CetuximabDrug

    Intravenous cetuximab at a dose of 500 mg/m²

  • Nab paclitaxelDrug

    Intravenous nab-paclitaxel at a dose of 125 mg/m².

  • GemcitabineDrug

    Intravenous Gemcitabine at a dose of 1000 mg/m².

  • FluorouracilDrug

    Intravenous Fluorouracil at a dose of 2400 mg/m² via 46-hour infusion.Dosing may follow the above regimen or local institutional standards.

  • LeucovorinDrug

    Intravenous leucovorin at a dose of 400 mg/m².Dosing may follow the above regimen or local institutional standards.

  • IrinotecanDrug

    Intravenous irinotecan at a dose of 150 mg/m².Dosing may follow the above regimen or local institutional standards.

  • OxaliplatinDrug

    Intravenous oxaliplatin at a dose of 85 mg/m².Dosing may follow the above regimen or local institutional standards.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib:Incidence of Dose-Limiting Toxicity (DLT) EventsTime frame: First 28 days (21 days for AG (3-week cycle))
  2. Phase Ib:Incidence and Severity of Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: From the first dose until 30 days after the last dose, assessed up to 24 months
  3. Phase II:Objective Response Rate (ORR)Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
  4. Phase Ib: Number of participants with abnormality in hematology laboratory parametersTime frame: up to 24 months
  5. Phase Ib: Number of participants with abnormality in clinical chemistry laboratory assessmentsTime frame: up to 24 months
  6. Phase Ib: Number of participants with abnormality in body temperatureTime frame: up to 24 months
  7. Phase Ib: Number of participants with abnormality in blood pressureTime frame: up to 24 months
  8. Phase Ib: Number of participants with abnormality in Physical Examination FindingsTime frame: up to 24 months
  9. Phase Ib: Number of participants with abnormality in PR intervalTime frame: up to 24 months
  10. Phase Ib: Number of participants with abnormality in corrected QT interval using Frederica's formula (QTcF)Time frame: up to 24 months

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Concord Cancer Centre, Concord Repatriation General Hospital, Sydney Local Health District

    Concord, New South Wales, Australia · Not yet recruiting

  • Macquarie University / Clinical Trials Unit

    North Ryde, New South Wales, Australia · Recruiting

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia · Not yet recruiting

  • Monash Health (Monash Medical Centre)

    Clayton, Victoria, Australia · Recruiting

  • Northern Health

    Epping, Victoria, Australia · Not yet recruiting

  • PASO Medical

    Frankston, Victoria, Australia · Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • The Third Affiliated Hospital (Cancer Hospital) of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Not yet recruiting

  • Shandong First Medical University Affiliated Tumor Hospital

    Jinan, Shandong, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.